Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma
NCT04299113 is a phase 1 interventional trial sponsored by Jonsson Comprehensive Cancer Center. As of 21 Nov 2026, it is active and no longer recruiting. It studies Mocetinostat and Vinorelbine in Rhabdomyosarcoma. The registry lists an enrollment of 14 participants at 1 site in 1 country. The registry lists a start date of 14 May 2020 and a primary completion date of 30 Dec 2026.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04299113 |
| Status | Active not recruiting |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Jonsson Comprehensive Cancer Center |
| Enrollment | 14 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Rhabdomyosarcoma |
| Drugs | Mocetinostat and Vinorelbine |
| Start | 14 May 2020 |
| Primary completion | 30 Dec 2026 |
| Study completion | 30 Dec 2027 |
| Last update posted | 17 Jul 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Noah C. Federman, MD
University of California at Los Angeles
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Rebecca Phelan
Los Angeles
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT04299113
Each answer restates registry values shown on this page.
What is NCT04299113?
NCT04299113 is a phase 1 interventional trial sponsored by Jonsson Comprehensive Cancer Center. It studies Mocetinostat and Vinorelbine in Rhabdomyosarcoma.
Is NCT04299113 recruiting?
As of 21 Nov 2026, it is active and no longer recruiting.
Who leads NCT04299113?
The registry names Noah C. Federman, MD (principal investigator, University of California at Los Angeles) as the overall official.
Where does NCT04299113 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT04299113 study?
The registered drug and biological interventions are Mocetinostat and Vinorelbine.
When is NCT04299113 expected to complete?
The registry lists a primary completion date of 30 Dec 2026 and a study completion date of 30 Dec 2027. The sponsor last updated the record on 17 Jul 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.